Today's Trend
Vir Biotechnology, Inc. (NASDAQ: VIR) has edged higher as investors weigh continued analyst support against a broad deterioration in HC Wainwright’s earnings outlook. The stock remains volatile, with the company still expected to report substantial losses in the coming years.
- Bank of America Securities initiated or reiterated a Buy rating on Vir Biotechnology, signaling confidence in the company’s longer-term prospects. No price target was provided in the report. Vir Biotechnology Receives a Buy from Bank of America Securities
- HC Wainwright maintained its Buy rating. The firm raised its Q2 2027 EPS forecast to a loss of $0.61 from a loss of $0.68 and improved its FY2030 estimate to a loss of $0.34 from a loss of $0.36, suggesting some longer-term potential for reduced losses. Vir Biotechnology analyst estimates
- Vir Biotechnology’s Q2 2026 earnings-call transcript was published. The supplied report provides the transcript link but no specific new clinical, financial, or pipeline updates; investors will likely focus on management commentary regarding development programs, cash use, and the path toward profitability. Vir Biotechnology Q2 2026 Earnings Call Transcript
- HC Wainwright reduced its FY2026 EPS forecast to a loss of $1.89 from $1.55 and cut FY2027 to a loss of $2.37 from $2.22. It also lowered estimates for Q3 and Q4 2026, Q1 2027, FY2028, and FY2029. These revisions point to higher expected losses and may pressure the stock despite the firm’s Buy rating.
Investor takeaway: The positive ratings from Bank of America and HC Wainwright are supportive, but the more immediate earnings revisions are unfavorable. VIR’s near-term direction is likely to depend on whether management’s earnings-call commentary can offset concerns about increased cash burn and delayed profitability.